查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925212

环糊精市场（按产品类型、给药途径、治疗领域和应用划分）－全球预测（2026-2032 年）

Cyclodextrin in Pharma Market by Product Type, Route Of Administration, Therapeutic Area, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，医药环糊精市场规模为 13.8 亿美元，预计到 2026 年将成长至 15 亿美元，预计到 2032 年将达到 22 亿美元，复合年增长率为 6.86%。

主要市场统计数据
基准年 2025 13.8亿美元
预计年份：2026年 15亿美元
预测年份：2032年 22亿美元
复合年增长率 (%) 6.86%

为环糊精在现代治疗製剂开发、监管管道和临床应用中的应用奠定基础

环糊精已从最初的辅料发展成为现代药物研发的关键製剂平台，在提高药物溶解度、标靶递送和改善药物稳定性方面发挥着重要作用。本文全面说明了环糊精应用的理化基础，重点在于分子包合物的形成、各种β-和γ-同系物的安全性，以及不断扩展的修饰衍生物及其潜在应用。我们阐述如何将这些特性转化为实用的製剂工具，从而提高传统上难以处理的原料药（API）的临床生物利用度，并改善患者的用药体验。

衍生物化学、监管演变和递送技术的创新如何重塑药物研发管线中辅料的选择和开发策略？

环糊精领域正经历变革性的转变，这主要得益于衍生物化学的进步、监管力度的加强以及药物递送设计领域的跨学科创新。当传统的β-环糊精无法满足溶解度或安全性方面的要求时，羟丙基和磺丁基衍生物等改性环糊精越来越受到青睐，而持续的合成改进正在提升批次间的一致性和功能性能。同时，一些创新公司正在将基于环糊精的策略整合到标靶递送系统和缓释系统中，利用包合物来调节释放动力学并减少药物在非标靶部位的暴露。

评估2025年美国关税对药品辅料采购、供应链韧性和合约风险的策略和营运影响

美国将于2025年实施新的关税，这将在全球医药供应链中造成复杂的动态变化，并对辅料采购、价格波动和合约风险分配产生实际影响。关税压力促使製造商重新评估其供应商多元化策略，并仔细审查总到岸成本，而不仅仅是单位价格。因此，采购部门正在将关税情境纳入供应商选择标准，而法务部门正在更新主供应协议，以反映关税转嫁或减免条款。

分析产品类型、给药途径、功能用途和治疗领域细分，以使环糊精的选择符合技术和监管方面的优先事项。

细緻的細項分析揭示了不同产品类型、给药途径、应用和治疗领域的影响差异，为相关人员提供了优先进行研发活动的参考依据。改质环糊精和天然环糊精之间的产品类型差异会影响製剂策略和监管依据。改质环糊精，例如羟丙基β-环糊精、甲基β-环糊精和磺丁基醚β-环糊精，具有特殊的溶解性和安全性，而天然α-环糊精、β-环糊精和γ-环糊精在结构简单的包合物即可满足需求时仍然适用。这些化学选择会引发製程的考量和杂质控制策略，进而影响下游生产和分析工作量。

美洲、欧洲/中东/非洲和亚太地区的地理监管要求、生产能力和采购实践如何影响环糊精策略和商业化

区域趋势对采购、监管策略和商业性应用有显着影响。美洲、欧洲、中东和非洲地区以及亚太地区各自拥有不同的营运和政策环境。在美洲，法规结构强调辅料安全性和品质的充分记录，采购实践也日益重视供应商的透明度、可追溯性以及支持无菌药品供应链的能力。此外，在临床上获益明确且有充分数据支持的情况下，先进的製剂方法也得到了快速应用。

从产品创新、监管文件、生产规模和策略伙伴关係关係等分析环糊精价值链中的竞争对手。

主要企业已观察到，环糊精领域的竞争优势源自于化学创新、品质系统、法规支援和供应链稳健性等综合能力。那些将技术差异化的产品系列组合与完善的杂质控制、可扩展的GMP生产以及积极的监管沟通相结合的企业，引领着产业发展。辅料供应商与药物研发企业之间的合作关係正从纯粹的交易关係转向策略联盟，供应商通常会提供配方支援、毒理学资料整理和法规文件，以加速新型环糊精衍生物的应用。

协调环糊精基开发专案中的製剂科学、采购弹性和监管准备的可行策略倡议

产业领导者可以透过采取一系列切实可行的措施，协调科学、供应和商业策略，从而获得显着收益。首先，应加快製剂科学家、法规官员和采购团队之间的跨职能协作，以便在辅料选择时同时考虑性能合规性和采购风险。其次，对于对给药途径敏感的产品，应优先考虑供应商合格流程，重点关注原料来源、杂质控制和无菌生产能力，以降低研发过程中的不确定性和潜在的监管询问。

透过整合专家访谈、监管分析、分析表征和供应链评估的调查方法，产生决策支援见解。

本研究主要透过对配方科学家、采购人员和法规专家的访谈，并辅以对同行评审论文、法规指导文件和製造商技术文件的文献综述。研究方法强调三角验证，将专家访谈的见解与官方法规立场和原始技术规范检验交叉验证，从而确保研究的科学严谨性和实用性。此外，本研究也着重于特定製程路线的要求，以及用于表征包合物、残留溶剂和潜在杂质的独特分析方法。

整合决定环糊精在製药和治疗领域成功应用的技术、监管和供应链要素。

总之，环糊精在製剂创新和监管控制的交汇点占据关键地位，为解决不同治疗领域的溶解度、稳定性和递送难题提供了切实可行的途径。改质环糊精和天然环糊精的化学性质之间的相互作用、不同给药途径的限制以及特定临床应用所需的调整，凸显了采用严谨的跨职能方法选择辅料的重要性。透过协调技术检验、监管文件和稳健的采购流程，企业可以释放环糊精的潜力，实现治疗方法差异化并改善患者预后。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 环糊精在製药业的市场（依产品类型划分）

  • 变性
    • 羟丙基β
    • 甲基β
    • 磺丁基醚β
  • 自然的
    • 阿尔法
    • 测试版
    • 伽玛

9. 依给药途径分類的环糊精药用市场

  • 鼻内给药
    • 滴鼻剂
    • 喷
  • 眼科
  • 口服
    • 液体
      • 悬浮液
      • 糖浆
    • 固态剂型
      • 胶囊
      • 粉末
      • 药片
  • 肠外给药
    • 肌肉内注射
    • 静脉注射
  • 外用药物
    • 奶油
    • 凝胶
    • 软膏

10. 环糊精在製药领域的市场（依治疗领域划分）

  • 循环系统
    • 抗高血压药物
    • 降血脂药物
  • 中枢神经系统
    • 抗忧郁剂
    • 神经保护剂
  • 感染疾病
    • 抗生素
    • 抗病毒药物
  • 肿瘤学
    • 化疗药物
    • 免疫治疗药物

第十一章 依应用分類的环糊精在製药领域的市场

  • 药物输送系统
    • 控释
      • 缓释
      • 缓释
    • 精准投放
  • 溶解度提高
  • 稳定性提高
  • 味道掩盖

12. 各地区环糊精在製药领域的市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 环糊精在製药领域的市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国环糊精医药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国药用环糊精市场

第十七章：中国医药环糊精市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ashland Global Holdings Inc
  • BASF SE
  • Caldic BV
  • Cargill Incorporated
  • Cerbios-Pharma SA
  • CycloChem Technologies Pvt. Ltd.
  • CycloLab Ltd.
  • Daicel Corporation
  • Hebei Tianxu BIoTechnology Co Ltd
  • Hubei Guangji Pharmaceutical Co Ltd
  • Jiangsu Zhiyuan BIoTechnology Co Ltd
  • Kleptose
  • Kuraray Co Ltd
  • Ligand Pharmaceuticals Incorporated
  • Merck KGaA
  • Nihon Shokuhin Kako Co Ltd
  • Roquette Freres
  • Samyang Corporation
  • Shandong Binzhou Zhiyuan BIoTechnology Co Ltd
  • Shandong Tianli Pharmaceutical Co Ltd
  • Shandong Xinda BIoTechnology Co Ltd
  • Shandong Yunzhou BIoTechnology Co Ltd
  • Shijiazhuang Hongwei BIoTechnology Co Ltd
  • Sichuan Kelong Chemical Co Ltd
  • Tokyo Chemical Industry Co., Ltd.
  • Wacker Chemie AG
  • Wuhan Sinobiological Technology Co Ltd
  • Zhejiang Huakang Pharmaceutical Co Ltd
  • Zibo Qianhui Biological Technology Co Ltd
  • Zibo Shuangfeng Chemical Co Ltd
  • Zibo Zhenhua Chemical Co Ltd
Product Code: MRR-F774F6336ADC

The Cyclodextrin in Pharma Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.50 billion in 2026, with a CAGR of 6.86%, reaching USD 2.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.50 billion
Forecast Year [2032] USD 2.20 billion
CAGR (%) 6.86%

Establishing the foundational rationale for cyclodextrin adoption across formulation development, regulatory pathways and clinical translation in modern therapeutics

Cyclodextrins have evolved from niche excipients to critical formulation enablers across modern pharmaceutical development, underpinning advances in solubility enhancement, targeted delivery and stability improvement. This introduction synthesizes the physicochemical rationale for cyclodextrin use, emphasizing molecular inclusion complexation, safety profiles across various beta and gamma homologues, and the expanding portfolio of modified derivatives that broaden application possibilities. It maps how these attributes translate into practical formulation levers that enable previously intractable APIs to achieve clinically viable bioavailability and acceptable patient experience.

The narrative begins by framing cyclodextrins within the lifecycle of drug development, from preformulation screening through late-stage manufacturing. It then addresses the interplay between formulation performance and regulatory expectations, noting how excipient provenance, impurity controls and sterilization considerations influence selection across parenteral, ophthalmic and other sensitive administration routes. Finally, the introduction sets out the analytical perspective taken in this report: pragmatic, scientifically grounded, and oriented toward decision-relevant implications for formulation scientists, regulatory leads and commercial strategists. By establishing this baseline, readers are prepared to interpret subsequent sections that explore market dynamics, segmentation nuances and regional policy impacts.

How derivative chemistry, regulatory evolution, and delivery innovation are reshaping excipient selection and development strategies across pharmaceutical pipelines

The cyclodextrin landscape is undergoing transformative shifts driven by advances in derivative chemistry, heightened regulatory scrutiny and cross-disciplinary innovation in drug delivery design. Modified cyclodextrins such as hydroxypropyl and sulfobutyl derivatives are increasingly preferred when conventional beta cyclodextrins do not meet solubility or safety constraints, and ongoing synthetic refinements are enhancing batch consistency and functional performance. Concurrently, innovators are integrating cyclodextrin-based strategies into targeted delivery constructs and controlled-release systems, leveraging inclusion complexation to modulate release kinetics and reduce off-target exposure.

Regulatory pathways are evolving in parallel, with agencies placing greater emphasis on excipient characterization, impurity profiling and clinical justification for novel excipient use. This regulatory tightening is accelerating demand for well-documented safety packages and harmonized quality standards for both natural and modified cyclodextrin variants. Moreover, the industry is witnessing a shift in clinical formulation priorities: there is higher tolerance for advanced excipients when they demonstrably reduce toxicities, enable less invasive routes of administration, or materially improve patient adherence. Together, these forces are reshaping R&D investment patterns, supplier relationships and the types of technical dossiers now expected by regulators and contract manufacturers alike.

Assessing the strategic and operational ramifications of United States tariff measures implemented in 2025 on pharmaceutical excipient sourcing, supply chain resilience and contractual risk

The imposition of new tariffs in 2025 by the United States introduced a compounding factor for global pharmaceutical supply chains that has practical implications for excipient sourcing, pricing dynamics and contractual risk allocation. Tariff pressures have prompted manufacturers to reassess supplier diversification and to scrutinize total landed cost rather than unit price alone. As a result, procurement teams are integrating customs duty scenarios into supplier qualification criteria, and legal teams are updating master supply agreements to reflect potential duty pass-through or mitigationclauses.

Operational responses to tariff-induced disruption include nearshoring certain production steps, qualifying secondary suppliers in tariff-exempt jurisdictions, and adjusting inventory policies to preserve clinical supply continuity. Formulation groups are also re-evaluating backward integration options for key excipients where strategic control reduces exposure to cross-border policy volatility. Importantly, these adaptations are not isolated; they have cascading effects on development timelines, CMO selection, and capital allocation for manufacturing assets. In aggregation, the tariff environment of 2025 has intensified focus on supply chain resilience planning, regulatory harmonization for excipient acceptance, and the need for closer collaboration between commercial, manufacturing and regulatory teams to keep development programs on schedule.

Dissecting product-type, administration route, functional application, and therapeutic-area segmentation to align cyclodextrin selection with technical and regulatory priorities

A nuanced segmentation analysis reveals distinct implications across product types, administration routes, applications and therapeutic areas that stakeholders must account for when prioritizing development activities. Product-type distinctions between modified and natural cyclodextrins influence both formulation strategy and regulatory substantiation: modified variants such as hydroxypropyl beta, methyl beta and sulfobutyl ether beta offer tailored solubility and safety profiles, while natural alpha, beta and gamma cyclodextrins retain relevance where simpler inclusion complexation suffices. These chemical choices cascade into processing considerations and impurity control strategies that affect downstream manufacturing and analytical burden.

Route-of-administration segmentation underscores how performance requirements diverge by clinical intent. Nasal applications require formulations compatible with drops and sprays that balance residence time and mucosal tolerability; ophthalmic use is narrowly focused on drop formulations demanding stringent sterility and ocular tolerance; oral delivery spans liquid and solid presentations, where liquids include suspensions and syrups and solids encompass capsules, powders and tablets with differing excipient interactions; parenteral routes, specified as intramuscular and intravenous, impose the highest sterility and impurity standards; and topical preparations, delivered as creams, gels and ointments, emphasize local tolerance and vehicle compatibility. Application-driven segmentation further clarifies development priorities: when cyclodextrins are leveraged for drug delivery systems the focus shifts to controlled and targeted delivery architectures, with controlled-release programs evaluating both extended and sustained release strategies; when the priority is solubility enhancement or stability improvement the chief concerns are complexation efficiency and degradation pathways; and when taste masking is central to patient acceptance, sensory testing and excipient selection become predominant.

Therapeutic-area segmentation links formulation imperatives to clinical endpoints and safety tolerances. Cardiovascular applications gravitate toward antihypertensive and lipid lowering agents where systemic exposure and long-term safety are paramount. Central nervous system programs, including antidepressants and neuroprotective agents, require consideration of blood-brain barrier permeability and excipient influence on CNS pharmacokinetics. Infectious disease workstreams that involve antibiotic and antiviral agents can prioritize high-concentration aqueous formulations or targeted delivery to infected tissues, while oncology preparations-spanning chemotherapeutic and immunotherapy agents-must reconcile potent APIs with excipient-mediated modulation of toxicity and delivery to tumor microenvironments. Understanding these intersecting segmentation layers enables teams to align formulation pathways, analytical strategies and clinical development plans with both scientific feasibility and regulatory expectations.

How geographic regulatory expectations, manufacturing capabilities, and procurement practices across the Americas, Europe Middle East & Africa, and Asia-Pacific shape cyclodextrin strategy and commercialization

Regional dynamics exert a significant influence on sourcing, regulatory strategy and commercial adoption, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational and policy landscapes. In the Americas, regulatory frameworks emphasize well-documented excipient safety and quality, and procurement practices increasingly favor supplier transparency, traceability and the ability to support sterile pharmaceutical supply chains. This region also shows rapid adoption of advanced formulation approaches when clinical benefits are clear and supported by robust data packages.

Within Europe, the Middle East & Africa, stakeholders contend with a wide range of regulatory sophistication and market access pathways. European regulatory agencies have stringent excipient characterization expectations, which encourages centralized dossiers and harmonized quality standards, while markets within the Middle East and Africa may present varied acceptance criteria, necessitating adaptive regulatory strategies and flexible commercial models. In contrast, the Asia-Pacific region is characterized by both manufacturing scale and active innovation, with many suppliers offering a broad array of modified cyclodextrin chemistries. Regional policy priorities in Asia-Pacific include local manufacturing incentives and an emphasis on export competitiveness, which can create advantages for companies able to align supply strategies with local regulatory and industrial policies. Cross-regionally, companies are responding by tailoring supply chain architectures, regulatory submissions and commercial engagement to the idiosyncrasies of each geographic cluster, thereby optimizing access to clinical and commercial opportunities while mitigating policy and logistical risk.

Examining how product innovation, regulatory documentation, manufacturing scale, and strategic partnerships differentiate companies competing in the cyclodextrin value chain

Key company insights reveal that competitive differentiation in the cyclodextrin space derives from integrated capabilities across chemistry innovation, quality systems, regulatory support and supply-chain robustness. Leading organizations are those that pair technically differentiated product portfolios with documented impurity control, scalable GMP manufacturing and proactive regulatory engagement. Alliances between excipient suppliers and pharmaceutical developers are increasingly strategic rather than transactional, with suppliers often providing formulation support, toxicology packages and regulatory-facing documentation to accelerate adoption of novel cyclodextrin derivatives.

Innovation leaders also invest in application-specific performance data, demonstrating how particular cyclodextrin grades perform in ophthalmic, parenteral or oral matrices, and how they interact with API classes relevant to cardiovascular, CNS, infectious disease and oncology programs. Contract manufacturers and finished-dose partners that can accommodate sterile processing and complex analytical requirements for parenteral and ophthalmic applications command strategic importance. Finally, companies that maintain geographically diversified manufacturing footprints and transparent supply chains are better positioned to respond to policy shifts and tariff pressures, providing customers with continuity of supply and the technical support necessary to de-risk development programs.

Actionable strategic initiatives to harmonize formulation science, procurement resilience, and regulatory readiness for cyclodextrin-enabled development programs

Industry leaders can extract tangible benefits by adopting a set of actionable initiatives that align science, supply and commercial strategy. First, accelerate cross-functional alignment between formulation scientists, regulatory leads and procurement teams to ensure excipient selections account for performance, compliance and sourcing risk simultaneously. Second, prioritize supplier qualification pathways that emphasize provenance, impurity control and sterile manufacturing capabilities for sensitive routes of administration, thereby reducing development uncertainty and potential regulatory queries.

Third, invest in targeted safety and application data for preferred cyclodextrin grades to build defensible dossiers that facilitate regulatory acceptance across diverse jurisdictions. Fourth, diversify sourcing strategies to include geographically distributed suppliers and to evaluate nearshoring or dual-sourcing where tariffs, logistics or geopolitical risk could threaten continuity. Fifth, embed scenario planning for policy shifts into procurement and development roadmaps so that duty impacts, customs delays or regulatory divergences can be anticipated and mitigated. By implementing these measures, organizations can reduce technical risk, shorten time-to-clinic for challenging APIs, and create more resilient supply chains that align with strategic growth priorities.

Methodological framework integrating expert interviews, regulatory analysis, analytical characterization, and supply-chain assessment to produce decision-ready insights

This research synthesizes primary interviews with formulation scientists, procurement leaders and regulatory specialists, augmented by secondary literature review of peer-reviewed publications, regulatory guidance documents and manufacturer technical dossiers. The approach prioritizes triangulation: insights derived from expert interviews were cross-validated against public regulatory positions and supplier technical specifications to ensure both scientific rigor and practical relevance. Attention was given to route-specific requirements and to the distinct analytical methodologies used to characterize inclusion complexes, residual solvents and potential impurities.

Analytical techniques considered include high-performance chromatography for derivative profiling, mass spectrometry for impurity identification, and in vitro dissolution and permeability assays to evaluate performance across oral, nasal, ophthalmic, parenteral and topical matrices. Regulatory review focused on excipient acceptance criteria, toxicology study expectations and sterility assurance levels applicable to parenteral and ophthalmic applications. Supply-chain assessment incorporated supplier audits, geographic footprint analysis and scenario modeling related to tariff exposure. Throughout, methodological choices emphasized reproducibility of findings, applicability to decision-makers, and clarity in translating technical data into operational recommendations.

Synthesis of technical, regulatory, and supply-chain imperatives that determine successful cyclodextrin deployment across formulation and therapeutic priorities

In conclusion, cyclodextrins occupy a pivotal position at the intersection of formulation innovation and regulatory stewardship, providing pragmatic pathways to address solubility, stability and delivery challenges across therapeutic areas. The interplay between modified and natural cyclodextrin chemistries, the constraints imposed by different routes of administration, and the tailoring required for specific clinical applications underscore the importance of a disciplined, cross-functional approach to excipient selection. When companies align technical validation, regulatory documentation and resilient sourcing, they unlock the potential of cyclodextrins to enable therapeutic differentiation and improve patient outcomes.

Looking forward, success will hinge on the ability to generate application-specific performance evidence, to navigate evolving regulatory expectations for excipients, and to structure supply chains that are responsive to geopolitical and tariff-related risks. Firms that proactively invest in these capabilities will find cyclodextrins an increasingly valuable tool in the formulation toolbox, particularly for complex APIs and delivery modalities that demand both scientific precision and operational reliability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclodextrin in Pharma Market, by Product Type

  • 8.1. Modified
    • 8.1.1. Hydroxypropyl Beta
    • 8.1.2. Methyl Beta
    • 8.1.3. Sulfobutyl Ether Beta
  • 8.2. Natural
    • 8.2.1. Alpha
    • 8.2.2. Beta
    • 8.2.3. Gamma

9. Cyclodextrin in Pharma Market, by Route Of Administration

  • 9.1. Nasal
    • 9.1.1. Drops
    • 9.1.2. Sprays
  • 9.2. Ophthalmic
  • 9.3. Oral
    • 9.3.1. Liquid
      • 9.3.1.1. Suspensions
      • 9.3.1.2. Syrups
    • 9.3.2. Solid
      • 9.3.2.1. Capsules
      • 9.3.2.2. Powders
      • 9.3.2.3. Tablets
  • 9.4. Parenteral
    • 9.4.1. Intramuscular
    • 9.4.2. Intravenous
  • 9.5. Topical
    • 9.5.1. Creams
    • 9.5.2. Gels
    • 9.5.3. Ointments

10. Cyclodextrin in Pharma Market, by Therapeutic Area

  • 10.1. Cardiovascular
    • 10.1.1. Antihypertensive Agents
    • 10.1.2. Lipid Lowering Agents
  • 10.2. Central Nervous System
    • 10.2.1. Antidepressants
    • 10.2.2. Neuroprotective Agents
  • 10.3. Infectious Diseases
    • 10.3.1. Antibiotic Agents
    • 10.3.2. Antiviral Agents
  • 10.4. Oncology
    • 10.4.1. Chemotherapeutic Agents
    • 10.4.2. Immunotherapy Agents

11. Cyclodextrin in Pharma Market, by Application

  • 11.1. Drug Delivery System
    • 11.1.1. Controlled Release
      • 11.1.1.1. Extended Release
      • 11.1.1.2. Sustained Release
    • 11.1.2. Targeted Delivery
  • 11.2. Solubility Enhancement
  • 11.3. Stability Improvement
  • 11.4. Taste Masking

12. Cyclodextrin in Pharma Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cyclodextrin in Pharma Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cyclodextrin in Pharma Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cyclodextrin in Pharma Market

16. China Cyclodextrin in Pharma Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ashland Global Holdings Inc
  • 17.6. BASF SE
  • 17.7. Caldic B.V.
  • 17.8. Cargill Incorporated
  • 17.9. Cerbios-Pharma SA
  • 17.10. CycloChem Technologies Pvt. Ltd.
  • 17.11. CycloLab Ltd.
  • 17.12. Daicel Corporation
  • 17.13. Hebei Tianxu Biotechnology Co Ltd
  • 17.14. Hubei Guangji Pharmaceutical Co Ltd
  • 17.15. Jiangsu Zhiyuan Biotechnology Co Ltd
  • 17.16. Kleptose
  • 17.17. Kuraray Co Ltd
  • 17.18. Ligand Pharmaceuticals Incorporated
  • 17.19. Merck KGaA
  • 17.20. Nihon Shokuhin Kako Co Ltd
  • 17.21. Roquette Freres
  • 17.22. Samyang Corporation
  • 17.23. Shandong Binzhou Zhiyuan Biotechnology Co Ltd
  • 17.24. Shandong Tianli Pharmaceutical Co Ltd
  • 17.25. Shandong Xinda Biotechnology Co Ltd
  • 17.26. Shandong Yunzhou Biotechnology Co Ltd
  • 17.27. Shijiazhuang Hongwei Biotechnology Co Ltd
  • 17.28. Sichuan Kelong Chemical Co Ltd
  • 17.29. Tokyo Chemical Industry Co., Ltd.
  • 17.30. Wacker Chemie AG
  • 17.31. Wuhan Sinobiological Technology Co Ltd
  • 17.32. Zhejiang Huakang Pharmaceutical Co Ltd
  • 17.33. Zibo Qianhui Biological Technology Co Ltd
  • 17.34. Zibo Shuangfeng Chemical Co Ltd
  • 17.35. Zibo Zhenhua Chemical Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYCLODEXTRIN IN PHARMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY HYDROXYPROPYL BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY METHYL BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SULFOBUTYL ETHER BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIPID LOWERING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIBIOTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ANTIVIRAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLUBILITY ENHANCEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY STABILITY IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TASTE MASKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CYCLODEXTRIN IN PHARMA MARKET SIZE, BY CONTROLLED RELEASE, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL CYCLODEXTRIN IN PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY MODIFIED, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN CYCLODEXTRIN IN PHARMA MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN CYCLODEX